Personalized Treatment of PLA2R-Related Membranous Nephropathy.
作者信息
Fernández-Juárez Gema, Ronco Pierre, Jha Vivekanand
机构信息
Department of Nephrology, Instituto de Investigación de la Paz (IdIPAZ), Hospital Universitario La Paz, Madrid, Spain.
Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1155, Sorbonne Université, Paris, France.
出版信息
Clin J Am Soc Nephrol. 2023 Apr 1;18(4):530-532. doi: 10.2215/CJN.0000000000000086. Epub 2023 Jan 27.
Abstract
摘要
相似文献
1
Personalized Treatment of PLA2R-Related Membranous Nephropathy.磷脂酶A2受体相关膜性肾病的个体化治疗
Clin J Am Soc Nephrol. 2023 Apr 1;18(4):530-532. doi: 10.2215/CJN.0000000000000086. Epub 2023 Jan 27.
2
Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.抗磷脂酶A2受体抗体与膜性肾病的免疫抑制：抗磷脂酶A2受体自身抗体致病性的更多证据
J Am Soc Nephrol. 2015 Oct;26(10):2308-11. doi: 10.1681/ASN.2015020181. Epub 2015 Mar 24.
3
Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.抗磷脂酶A2受体自身抗体指导下的膜性肾病诊断与治疗：一种新的个性化医疗方法。
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1341-3. doi: 10.2215/CJN.05880614. Epub 2014 Jul 17.
4
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.抗 M 型磷脂酶 A2 受体 (PLA2R) 自身抗体在鉴别特发性膜性肾病 (IMN) 与继发性及其他肾小球疾病中的诊断特异性。
J Nephrol. 2018 Apr;31(2):271-278. doi: 10.1007/s40620-017-0451-5. Epub 2017 Oct 28.
5
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.每月小剂量利妥昔单抗治疗原发性抗 PLA2R 阳性膜性肾病：一种个体化方法。
BMC Nephrol. 2023 May 26;24(1):146. doi: 10.1186/s12882-023-03206-1.
6
Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.抗磷脂酶A2受体自身抗体：原发性膜性肾病治疗的一大进展
Biomed Res Int. 2015;2015:249740. doi: 10.1155/2015/249740. Epub 2015 Oct 20.
7
Clinical significance of Mtype phospholipase A2 receptor and thrombospondin Type 1 domaincontaining 7A in primary membranous nephropathy.M型磷脂酶A2受体和含血小板反应蛋白1结构域7A在原发性膜性肾病中的临床意义
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Jun 28;45(6):693-700. doi: 10.11817/j.issn.1672-7347.2020.190109.
8
Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.根据抗M型磷脂酶A2受体抗体的存在情况，特发性膜性肾病的临床特征、病程及预后
Nefrologia. 2015;35(5):479-86. doi: 10.1016/j.nefro.2015.05.026. Epub 2015 Jul 7.
9
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.抗磷脂酶A2受体抗体滴度可预测利妥昔单抗治疗后膜性肾病的疗效。
J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.
10
Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.特发性膜性肾病预后评估和治疗选择中肾磷脂酶 A2 受体沉积的临床价值：一项回顾性队列研究。
Nephrology (Carlton). 2020 Mar;25(3):219-229. doi: 10.1111/nep.13691. Epub 2020 Jan 20.
引用本文的文献
1
Antigens in membranous nephropathy: discovery and clinical implications.膜性肾病中的抗原：发现与临床意义
Nat Rev Nephrol. 2025 Jul 21. doi: 10.1038/s41581-025-00980-z.
2
Clinical outcomes of immunosuppressive therapy in patients with seronegative anti-PLA2R antibodies and PLA2R-related membranous nephropathy.血清阴性抗PLA2R抗体及PLA2R相关膜性肾病患者免疫抑制治疗的临床结局
Clin Exp Nephrol. 2025 Jul 20. doi: 10.1007/s10157-025-02731-7.
Zotero 插件